Scholar Rock (NASDAQ:SRRK) CFO Vikas Sinha Sells 10,410 Shares of Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) CFO Vikas Sinha sold 10,410 shares of the stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $49.57, for a total value of $516,023.70. Following the completion of the transaction, the chief financial officer owned 619,856 shares of the company’s stock, valued at $30,726,261.92. This trade represents a 1.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scholar Rock Price Performance

NASDAQ SRRK opened at $47.80 on Tuesday. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.41. Scholar Rock Holding Corporation has a 1 year low of $27.07 and a 1 year high of $51.63. The company has a market cap of $5.49 billion, a PE ratio of -13.94 and a beta of 0.68. The stock’s 50-day moving average price is $46.16 and its two-hundred day moving average price is $42.12.

Scholar Rock (NASDAQ:SRRK) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.10. During the same quarter last year, the firm earned ($0.64) earnings per share. On average, analysts predict that Scholar Rock Holding Corporation will post -3.13 EPS for the current year.

Institutional Trading of Scholar Rock

Several hedge funds and other institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. increased its holdings in Scholar Rock by 161.0% in the third quarter. JPMorgan Chase & Co. now owns 713,988 shares of the company’s stock worth $26,589,000 after buying an additional 440,401 shares during the last quarter. Moody Aldrich Partners LLC lifted its stake in Scholar Rock by 53.5% in the third quarter. Moody Aldrich Partners LLC now owns 101,742 shares of the company’s stock valued at $3,789,000 after acquiring an additional 35,481 shares during the last quarter. Voya Investment Management LLC grew its position in Scholar Rock by 18.1% in the third quarter. Voya Investment Management LLC now owns 443,155 shares of the company’s stock worth $16,503,000 after acquiring an additional 67,839 shares in the last quarter. HighVista Strategies LLC grew its position in Scholar Rock by 90.8% in the third quarter. HighVista Strategies LLC now owns 59,573 shares of the company’s stock worth $2,218,000 after acquiring an additional 28,343 shares in the last quarter. Finally, Nan Fung Trinity HK Ltd. acquired a new position in shares of Scholar Rock during the 3rd quarter worth $1,402,000. 91.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on SRRK shares. Wedbush boosted their target price on shares of Scholar Rock from $56.00 to $58.00 and gave the company an “outperform” rating in a research note on Wednesday, April 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a research report on Thursday, January 22nd. Raymond James Financial restated a “strong-buy” rating on shares of Scholar Rock in a research report on Tuesday, March 3rd. Canaccord Genuity Group set a $62.00 target price on Scholar Rock in a research note on Monday. Finally, BMO Capital Markets upped their target price on Scholar Rock from $50.00 to $70.00 and gave the company an “outperform” rating in a report on Wednesday, March 4th. Four research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $55.40.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).